Form 8-K

0001193125-11-284106.txt : 20111027 0001193125-11-284106.hdr.sgml : 20111027 20111027160254 ACCESSION NUMBER: 0001193125-11-284106 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20111025 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20111027 DATE AS OF CHANGE: 20111027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 161590339 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 111161931 BUSINESS ADDRESS: STREET 1: 1380 WILLOW ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1380 WILLOW ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 d247687d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 25, 2011

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-34899

16-1590339

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1380 Willow Road

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02.

RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On October 27, 2011, Pacific Biosciences of California, Inc. announced its financial results for the third quarter ended September 30, 2011. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 8.01.

OTHER EVENTS

On October 25, 2011, the Board of Directors of Pacific Biosciences of California, Inc. appointed Michael W. Hunkapiller, Ph.D., as Executive Chairman of its Board of Directors. The material terms of Dr. Hunkapiller’s compensation arrangements, once finalized, will be disclosed in a subsequent filing.

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.


Exhibit Number		Description

99.1		Press Release dated October 27, 2011 titled “Pacific Biosciences of California Announces Third Quarter Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02).

99.2		Press Release dated October 27, 2011 title “Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Pacific Biosciences of California, Inc.

By:		/S/ SUSAN K. BARNES
		Susan K. Barnes Executive Vice President and Chief Financial Officer

Date: October 27, 2011

EXHIBIT INDEX


Exhibit Number		Description

99.1		Press Release dated October 27, 2011 titled “Pacific Biosciences of California Announces Third Quarter Financial Results” (furnished and not filed herewith solely pursuant to Item 2.02).

99.2		Press Release dated October 27, 2011 title “Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman”

EX-99.1 2 d247687dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

Pacific Biosciences of California, Inc. Announces

Third Quarter Financial Results

Menlo Park, Calif. – October 27, 2011 – Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the third quarter ended September 30, 2011.

During the third quarter of 2011, the Company recognized revenue from deliveries of its third generation sequencing platform, the PacBio RS, SMRT^® cell and reagent consumables, as well as revenue derived from instrument service contracts, totaling $10.5 million, compared to revenue recognized of $10.6 million for the second quarter of 2011. Net loss for the quarter increased to $29.3 million, including workforce reduction charges of $4.9 million, compared to the $22.5 million net loss recognized during the second quarter of 2011.

Gross profit for the third quarter totaled $3.3 million, resulting in a gross margin of 32%, compared to gross profit for the second quarter 2011 of $7.9 million and a gross margin of 74%. Gross margin for both the third and second quarter reflect the ongoing, but declining, margin positive impact of significant instrument component costs that were expensed during prior periods. During development, costs relating to instrument components and manufacturing costs were expensed until commercial production started.

Research and development expense during the third quarter of 2011 totaled $20.0 million representing a 2% increase compared to $19.5 million for the second quarter. The reported expense includes non-cash stock-based compensation totaling $1.6 million and $1.5 million for the third and second quarters of 2011, respectively.

Selling, general, and administrative expense during the third quarter of 2011 totaled $12.8 million representing a 16% increase compared to $11.0 million for the second quarter. The reported expense includes non-cash stock-based compensation totaling $1.4 million and $1.3 million for the third and second quarters of 2011, respectively.

As announced on September 20, 2011, in consideration of uncertainties associated with the economic environment and to position the Company for long-term success, the Company implemented a reduction of approximately 28% of its total workforce. During the third quarter the Company recorded reduction related charges totaling $4.9 million, comprised primarily of personnel separation costs paid during the third quarter and those expected to be paid during the fourth quarter. Research and development and sales, general and administrative expenses for the quarter include workforce reduction related charges of $3.5 million and $1.4 million, respectively.

Cash and investments at September 30, 2011 totaled $193.7 million compared to $216.6 million at June 30, 2011.

Quarterly Conference Call Information

Management will host a quarterly conference call to discuss its Third Quarter 2011 results today at 4:30pm Eastern / 1:30pm Pacific. Investors may listen to the call by dialing 866.831.6267, or if outside the U.S., by dialing +1.617.213.8857, and entering passcode 76006005. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/.

Forward-Looking Statements

This press release contains forward-looking statements relating to the Company’s operations and operating results, including statements relating to the Company’s margins and restructuring costs. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in Pacific Biosciences of California’s recently filed Quarterly Report on Form 10-Q, including those listed under the caption “Risk Factors.” Pacific Biosciences of California expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Trevin Rard

650.521.8450

ir@pacificbiosciences.com

Pacific Biosciences of California, Inc.

Unaudited Consolidated Statement of Operations

(amounts in thousands, except share and per share amounts)


	Quarters Ended
	September 30, 2011			June 30, 2011			September 30, 2010
Revenue:
Product revenue	$	9,819		$	10,148		$	—
Service and other revenue		535			192			—
Grant revenue		165			290			220

Total revenue		10,519			10,630			220

Cost of revenue:
Cost of product revenue		6,546			2,537			—
Cost of service and other revenue		645			194			—

Total cost of revenue		7,191			2,731			—

Gross profit		3,328			7,899			220

Operating expense:
Research and development		20,001			19,546			32,873
Sales, general and administrative		12,764			11,016			8,043

Total operating expense		32,765			30,562			40,916

Operating loss		(29,437	)		(22,663	)		(40,696	)
Other income (expense), net		156			188			(12	)

Net loss	$	(29,281	)	$	(22,475	)	$	(40,708	)

Basic and diluted net loss per share	$	(0.54	)	$	(0.42	)	$	(39.70	)

Shares used in computing basic and diluted net loss per share		54,283,162			53,413,565			1,025,326

Pacific Biosciences of California, Inc.

Unaudited Consolidated Statement of Operations

(amounts in thousands, except per share amounts)


	Year to Date
	September 30, 2011			September 30, 2010
Revenue:
Product revenue	$	19,966		$	—
Service and other revenue		728			—
Grant revenue		725			1,394

Total revenue		21,419			1,394

Cost of revenue:
Cost of product revenue		9,083			—
Cost of service and other revenue		839			—

Total cost of revenue		9,922			—

Gross profit		11,497			1,394

Operating expense:
Research and development		63,665			85,279
Sales, general and administrative		34,899			19,760

Total operating expense		98,564			105,039

Operating loss		(87,067	)		(103,645	)
Other income (expense), net		502			(102	)

Net loss	$	(86,565	)	$	(103,747	)

Basic and diluted net loss per share	$	(1.62	)	$	(134.07	)

Shares used in computing basic and diluted net loss per share		53,465,836			773,839

Pacific Biosciences of California, Inc.

Consolidated Balance Sheets

(amounts in thousands, except per share amounts)


	September 30, 2011		June 30, 2011		December 31, 2010 (1)
	(unaudited)		(unaudited)
Assets
Cash and investments	$	193,696	$	216,588	$	283,674
Accounts receivable		4,434		5,437		341
Inventory		20,262		19,552		6,864
Prepaid and other current assets		1,890		3,151		2,235

Total current assets		220,282		244,728		293,114
Property and equipment		17,359		16,180		12,311
Other assets		319		312		322

Total Assets	$	237,960	$	261,220	$	305,747

Liabilities and Stockholders’ Equity
Accounts payable	$	8,158	$	9,032	$	9,515
Deferred revenue		3,970		2,381		3,221
Accrued and other current liabilities		9,004		10,050		8,104

Total current liabilities		21,132		21,463		20,840
Facility financing and deferred rent		6,145		6,431		5,041
Stockholders’ equity		210,684		233,326		279,866


Total Liabilities and Stockholders’ Equity	$	237,961	$	261,220	$	305,747

Note 1:

The condensed consolidated balance sheet at December 31, 2010 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

EX-99.2 3 d247687dex992.htm PRESS RELEASE Press Release

Exhibit 99.2

LOGO

Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman

MENLO PARK, Calif. – October 27, 2011 – Pacific Biosciences of California, Inc. (NASDAQ: PACB), provider of Single Molecule Real Time (SMRT^®) sequencing products, today announced the appointment of Michael W. Hunkapiller, Ph.D., as Executive Chairman of its Board of Directors. Dr. Hunkapiller, a General Partner at Alloy Ventures and former President and General Manager of Applied Biosystems (now part of Life Technologies, NASDAQ: LIFE), has been a member of the PacBio Board since 2005. Hugh Martin remains the company’s President and Chief Executive Officer.

“Mike has been a driving force in the sequencing industry for three decades, and we are honored that he has agreed to take a more active role with PacBio,” said Hugh Martin. “We look forward to being able to draw more heavily on his expertise, experience and relationships with customers in the life science tools market.”

Dr. Hunkapiller commented: “I have spent much of my career on the leading edge of sequencing technology and I believe PacBio’s single molecule, real-time technology will disrupt the sequencing market. I am delighted that Hugh and the Board asked me to take on this newly created role and look forward to devoting more time to advising the company on how to accelerate adoption of their products in important applications.”

A renowned scientist, entrepreneur and life science industry executive, Dr. Hunkapiller spent 21 years at Applied Biosystems (ABI), which he co-founded and helped grow from startup to nearly $2 billion in annual revenues supplying instrument and reagent systems for life science research. He was also a founder of ABI’s sister company Celera Genomics and Senior Vice President of Applera Corp. (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology.

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com. You can also follow the company on twitter www.twitter.com/pacbio.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research. The company has developed a novel approach to studying the synthesis and regulation of DNA, RNA and proteins. Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, Pacific Biosciences has created a powerful technology platform called single molecule, real-time, or SMRT^®, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform the understanding of biological systems by providing a window into these systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may contain words such as “believe,” “may,” “estimate,” “anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of these terms, or other similar expressions, and include the assumptions that underlie such statements. Such statements include, but are not limited to, statements regarding the Company’s SMRT technology. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to risks discussed from time to time in documents Pacific Biosciences of California, Inc. has filed with the Securities and Exchange Commission, including the risks identified under the section captioned “Risk Factors” in its recently filed Quarterly Report on Form 10-Q. All forward-looking statements are based on estimates, projections and assumptions as of the date hereof. Pacific Biosciences undertakes no obligation to update any forward-looking statements.



Contacts:

Media:		Investors:
Nicole Litchfield		Trevin Rard
For Pacific Biosciences		Pacific Biosciences
415.793.6468		650.521.8450
nicole@bioscribe.com		ir@pacificbiosciences.com

GRAPHIC 4 g247687g97n42.jpg GRAPHIC begin 644 g247687g97n42.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`*0"N`P$1``(1`0,1`?_$`)\```$%``,!`0`````` M```````&!P@)"@$$!0,+`0$``00#`0$``````````````04&!PD"!`@#"A`` M``ZWL6B:Y;H36C`?*OBX^8'AQ*V`]A_@5O'N1C8-U]P[B3`[8G8U\ M4(8'WT\;A4/Y'>BV8YM"UTH?(=#T0TAQS\V7_(_\G\S*.)&*O.45!D9=4 M_HOE'_@5WFT?Y!=FY'ZS1Q'<\-T:\69XI!2CM:LV9@A.3SDR#5(\4HFA\2?:H)0 M][BNMV26&0]MZUUA(Y]N+'G^D8)I^UWMQE"&Q/RT>6S:$C8BI.;>_ MI*(NW>@76I@L^/,L!_IH`K[)G`W_`%]B+G.^PZ]8K],91JV9:3SEH\919C3V M$'K*=14AK7GU<4]LW/(&3EZ@RU>'EV\:Y M7:/I7*(#0[I7+-?8/[VYRMGQ6S-G("41:JK$$IS%"4$-WMBUH:8>^JK2W2Z. MW36S59LTSVWX10;1?-!IVDUZ9=,Y:MVB)3J;F/.T^M4Q7@D'W^@Y5A M(D=GG;VI:M0*AIU!X8Z%G:7?*W%6VJ2O]Y<[QYI6!FV24A%/`926PM'K07;1 M8A@363(,GK=%VS=M5DW#9TUB(]$1Z(CT1'HBSW?Y#O>]DY/Y>@,:RR<7@=:Z; MHJ/$-'W'Z$_:#P)7NCX(]DK#N=W&FW=N2%L^U]NB*7IN`""'LC M$;YGM.A166CK]<:W#6%_5,5YENFEP.;'FF1 M'80%VM4]8*.+VQ0YS_5(-HQHX^A4IBE.H'L8UBQV^);&WK7KNH0-(XG/:WZ. M<>(XK:5ENX??F?,7=OM'8<3\%:7$D39K_+6]I+=]-Q;U+>&.*YY8Y`*Q.F>S MF!!(;J`Z:/B'G99)/7Z[U9SW,\*)PNC0-"TL^[G^G']%;, MGRHL[8G:M_MG.0]Z#*V*/`C_B.L&ACC)>%X#.4@QU%#.#R8 M8UXY-&Z[[)BVR/,9YPCF%OL^$L;#SNM&H81GS&BOY.1@;471*\C/U] M-HZD%EH]5*,774*;Y$2$PU#-0XEV2+9;F6*YZ48J8ZQ4Y/221J*CQU%%ASX\ M;N[_`&`[6MR>$VKBLOM-F6RKW00Y%T63#CDKIUPUC98#:2F*4O9&ULK3*UK7 M"A=1)[QAZQNWB+\C=8@&FK371DK3Y'[3QU%?# M6H?(O;&R_E+V#N.Y&SHWMW=M]L\C62Q]*\A?;:W^,NXSZV2-8TO;&:TE;&Z, MEDA+]]/K*"TC*J#5FVXN?)^0N$2^50]A+P3$C-+ZS7[;8H=6('H:P`DG%-JA M9*T\;R0//83'6552%+]`)\OY@G@N7[OYJ-';^9]'S=MS-CI=GKVO;7MT;;.? MS6FMZVT6>/8^-CC3!`(51=8#> MH7%([HZ:VRGWG9"PW-N@\\5OLOD6\\U0L?)6O,Y]C*]&YCFUQE,*;0:><6ZS M?M$M:LV3F*RA^1^.+A=K'(I"8Q/8"E74\JVG/KIS7A-BRIQ'+YZ\RBBH59.+ M,E^-'1L=7(^-+"'12_\`QO8%5H9DY;G`JC9P@=(Y2G(8`*%5YJNFY5JG0/.\ MSD53;5^`@>D>_P"EV&Q1T5"QL1J5^K'&=U87;08A["**$L;=2;*I$+23C_D. M'<2L`B8A"&$N03A\$9=UL_X\Y.EZ_P!94^`IKC$\J?1M/<B5.'@YZU>/VETO(+'/N%?9JRC(W4)U@B1RL)$F[QV@83E'V]Y45T5V MN^W_`#C+,2U;0M>1C7F8U2A6>5N\7+-F#]C/5].*,E!"/EU[,17]O1 M9*^Y7JSDB'L/V>PPH2HS:192^=T*5C*J[HL;)TRKR$=27[)I&OJ>Q>0C%PSJ M[R.CSJ,8]U`-U"M%$$3&21.D)"")0#T1+7T1'HB/1$>B(]$1Z(CT18./\I:1 MFENV\4C7GVEA8_FB(_P`15449(D./L`B"10'^`>L9 M[S<1DXO(6Y(_-VO[`MU/]-JWM&=G\Q776E5E?"=\N] MNZ;K-V&T-D6V2AQF?O\`&QWSLK!:0$VDY8UTUO(Q]P"UA:7]/F#S7DY0:"3U M"Z(R#8N,/(-S3A^4/\[X,YZY,4O%;E]!1AI;5K_U5,:]GJ6?ZOI%FCF_X4== M+FK&+1[&'8+"U9QK8R29CE*":?U?=P3X?(6-K$68R&TX\'$@4 M:-1_8L:YW8>ZMJ=V-C=P=X9-E_WLSNYO;RLM2]EE;8:.QNS=65I$X\SX(`]L MLD\C>>29X>X-<>9U?WF`F(>=[3?2$'+1DW'_`/P#E%I^=$2#239"Y85[7,=1V5O'--'`&CFD$&FH((2^ZA<3\7X_P#Q&.;@=PAK[1[T M;)T8SL526A'!":I4'&2J.C&#\LD&:S)2YX'Y>Y?PQ$4?Z7Q]1>U;B<=U=)@Y M_+Y]+F!9]:5I14+MM'87/?+NC%B@T[5IT3;BX`_U M*!_JJOTFX19TYAHEP_*)'R\8P6>%$OP$KM5JD=P42>Q?@)5C"'M[![>LPM)+ M03XT7Y^+MD4=W*R#6%LC@WCZ0XTU_!1MTF^9S!"AL)' M2M=K-%FI/,$+6^L"#-C7[1:(MF[BRVO\@X/$VIE!5*9/[?B42!*ZZ]"J37*N MJVY3J"CW_*-'G,]H4]0%]2J>FPMNKE*I$C(-;99F+EU#6.0J-?\`S'$"BX>O M%").C-V92G5^E/X@1=C:'O,-\QR(T':+KFAL/A9BC:]7]0FM&C*O18J5JTNQ MM-#OD/I3.P1$:T2;23=%=JZ2?@@Y3,)!%1)0Q#$K3P42,VQWQN]9N+Q<.:-D MK=X@;!,NI'5H/DSJ^R,\\L,W+*J&D7-YIN,Z0C66DC.JE.9TI^.T6?B)C*F4 M$QC"1+C4+GXR,%LV(9'K6N.3I*0W^EX MGK',/0S_`&.6_N'H*E4;7*/L!K*_95FOT4)"RU:,M%C)',V]?K4>U`46[=L5 M1N50/ZPB<2)L5<'\<&>IL;I>->K,A0LHT@*K!U_:>M9^WXOF.M5]/<\WNX31G!( M:ITW:KO6K.S4JQ0]JKSMS&NUF$BV;34$\?QJZ[!\W417(503)+$, M0P`8!`"+IQVG9M,5R?N,1H5'E:C57T]&6BU1UL@7UF*M@G3W/NUV:OE5/.5W*=BS M[0)R*20,":SA_$U6PRK]LU34,!15,F"8&_3Y>_HB^5B[,X_I\[+5>V]6\V5: MS0+]U%3M=L6Z9?"3L+*,5C-WL;+1$G:6LA'/V:Y!(JBLF11,X"!@`0]O1$HW M_3?-T7EBVYR70.),,3;N%VB^P.]5HK?+TG;9RLS<-#WY2=+50=(O$#HF2_+^ M952&((?(!#T1?+->H>:MEHL< M'-O8B%433#Y&*Z62,4OZB`!Z(EFAK>4NH"0M;;3<]<5>):L7TK9$+G7%H",9 M2;UQ&QKR0F$Y(TCQ# MB5D>?UI>JZ>W8HG7=)Y=<73-S'V4Z::9CF8U"UM_BX$!]DD)8ZQO9-(Y@LC> MMB^2U;D8A4P@A_\``[C^#2`3]*K9%_3J[L6&V]XY'M?FI6Q09P,FM'.(#?=P M-<'0U)`YIX35OFZ$,%7.:#4WVI.^.=*,X@C^K<_ZX?:6R\>/)#QM9N?KMEK* ML3]6<4Q\,7"2L%H4*Z=0\G'+I+%,]:K*E535`11^1?UH=^_%5M_>1W)N/9Q: MQN:!2AH*..A\=1YA>GNT5EW]==;RG[9WNUV;??OS-M,63M[QTLT%I!]>NE:O2?:M2NV0QW+'+&,(V M%K&7':-`59QH37[.F8QHV(:((QD<QLHO;V0=S4)YGO M]G\KA]TR=RNY67.X.Y$EN;>*40BWL["W<>9T%A;!S^ M3G-.M.]SI90`'$#G#EG0>@/&5G%>J]@+PEK&LZ]"5Z%1D(W6>D"GPV5NK%@U M2D+,^J%1HL/9Y2$D99-1U^RJR!6_UG!`YS$`1&8I<-`P$63;-;1JR;>4JM(DJM=M$;5^&)"9UE^(Y<_;.:UEM/ M@VI5(VM5J0>)(0D:Q()E#B[6<'%0Y7"H]K'1W.>S;'S^H-(<^FC6,;]K6CA4 M@`>?J/T5E=X\KLOXJ_'7(8W;),63O8Y;>U,DG4NKO(7C2);R>1QYII6@NN)I M#H`QL8#1TV+]';UEQ:!UDI\G4I1H;SWX.^O_``5B#W";L/0L97\Z3D,30'*(D$X-1"/DW,T MN5^HX6(5('`%(E1X[,NI7=NY>+GEWI6(9:!S5QEX0>4.J:7@EJ3_`#\\TC?M M><,*(.D7NI.3&A+Y%9W5(D&<L5X8UKQ^=^ MN7M+89-7XG.X+?\!Z+L#FDW;-K[6:FTBX.VR$20$9.&=NV MR[F-5:&.F/\`*G]9%#^JX1/\,63LRO=W>&ZR>1O/NA.B-JV!]W'A%-RCJ/1[ MSE>D3KY_`5:_9;>\B:O&)LJY+$KF0V>Y"WD:_() M&_)B(QB!_N2*@N)%?'TGXN^&9.8YXVFIP^;\-Z=S/L5!NN<;EAU:S'&I==JT M?A%.\6M3M.)BH.TYUIS5\$6[AGA5?N%0I6X%,#;5;P&ZEPU98ZNW:7A.D[SR[RKG4-2G;2K2B2C)&X9C;IR MXQ4I9V;E6/0_&1]E?R#)J&!,QQ]$5-W@,T2[^-_'.*;E?;'+S7!OE+G;G5EI M:75$T1RMWE#:M?*'4&2[L03;1.8].TRHLV21C>Y6MECB?8=)(XF5(D9SM7&W M1]]XU\=NDOW:7,O2?EQ\T>S]#45*0>1+/:$.2KFUNF?9!9#L5FJTK3I:UV#\ MZ8C#G^IX@Q3]P^29!*1:5NF_%MPG,*8+K=6APK\%DG(+`5(H',('(L\')-DQR$Z)\M*5 M^\*6H^1>6<^5OJMPVV6B\\\XZS#55@HYJPDS16?V.TP-D9/X=S]D@=H@D=H0 MDF0X'^Q10`(IV]7M( M*N[1&9P1Q*8)9[S5EH5U(I,WBRRATY%-1`2N%EE$"+W>-5/'=L'D4O+6.YLZ M/\;?4FSX9UO&:]A.7=2YPE+-7KS4Z^%'&3HVC7'/HT5VJ.KCND5/5J/6<?7U'3JA M*&.[FEU(Y&&O2/[@1HT%!F98YP.D8JAP,13%G(.&L\++5RQ14?.5^>C7T-.0 MLLT0?Q+ M?0=>XU0J$O6\SQ*C8K'8"]E/[;GHBL9J6:3KPTRR6%\>$G$0C)`C?\5\Y9+I M_27X*+B?XDLC/[;NKB5MSC>4L9$UG3.AHVM"":@Z&E#3AJMFOQ.^9FS]E8N^ MVMW:-U%?Y',7&0?DFLZL1%,/Z1'"+!H8 MP@!W*8?KZ[UIMO+WC@',Z$7$R4K^31J3^)`6'NY/S@[%;"LG_P`IR`S^<`/) M;V'K87#PY[HCH,;7Q+72/`J1&[P6Y;@G@#"O'KCI,KQR/J0 M@>#&L8V><\SM=2Y%F>49BJ="9)?].B)&'G M];5U.2GXXE&T&@.&CW\AHQ;I?-P8"%36^13_`&%^!$VR'BVZZWG7K_T?W=U5 MD.E:U'\D[]ROS72\)Q6P9ACF0AT/65J[?=-GT;1?;O=[G9Y9H1LV,@9\BV1: M)F^'N<4Q3(NF'B`V7+'1G MLPUVA)S<7:$*@I9HPTO#NV#\LA$/%CJ%!104CHD2[IWC_P"V>E.B<'W[RA[M MS[<:IRG<5-/P7EWDVA7JN9$KM"<02+X5"M M6:2@JJB*R*Q$M)+@'R,=EW_#$O)MT)RF]YSY^U:G;DWP?C_,M-@@WO4,V>C) M9X]V2X:S9Y1W%TBOS0@_6KT6V6;OEB%(LL8"IJ)D3'Z/X2^C'M/N"N4](8]" M:JKYKK;Y<<^G+WF=NL5+BTI2"695W++;`1%KAI2;>,)8Q%GCML\:HN$`,0A4 MS"!P(K$L3S[R^M--K2W2G1'!-QQ$0F4+W6L@YOVVDZ-)M'4!*-HHM9M-JWFW M0$2NVGU6BRYG$I50\2E?\`%GTE/Q&N5Q&F:#5K M!=JO%.Z[],I:--MNDU2Z4YM).I!]`VK/YB<9/(YR*IS)2,>14/Y!^'HBA#C? M@0TO,N*L@RD>OU67;W,G66M]<\]=CPU(A>4'7-&'ZG2]J=8CQ]FFGP M+SH?0LTD4YB@%V.W:Q9)-6!H41/)$D',#$-UDWRI"D47_E241(D]E?C\\J_* M^J=CS_*?5'#T?FO5_7NO]8K06V\Y['=KE7)K4W$6D>!&=J&TT>*79QL5!M2> MP-#"*_VG`P%.!"D2\T[@/R(W:W8#V57>K>2>C3>BUN3KDRP2?H3<9+J+E=BI_1$@I_61*W$^#NR]+[-Q7N7 MR,;5SY9[MRW2=3J'-^+:OFU5E=KAV%;TB_7:[:A8):Z72;DJU&I,FC` MK5BP9_\`M+\E`-\R*Y_T1'HB/1%P7^`?[!_V#T'@N+?!`?Z_[^H'B5(7/J5* G/1$>B(]$1Z(CT1'HB/1$>B(]$1Z(CT1'HB/1$>B(]$1Z(CT1?__9 ` end